inPractice® - Rilpivirine and Acid-Reducing Agents

Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/1/18 (What's New)

Summary

Coadministration of rilpivirine, emtricitabine/rilpivirine/tenofovir DF, or emtricitabine/rilpivirine/tenofovir AF and H2RAs should be undertaken with caution as rilpivirine plasma concentrations may be significantly decreased^{[FDA Rilpivirine; FDA Emtricitabine/Rilpivirine/Tenofovir; FDA Emtricitabine/Rilpivirine/TAF]}
Rilpivirine, emtricitabine/rilpivirine/tenofovir DF, or emtricitabine/rilpivirine/tenofovir AF are strictly contraindicated with PPIs due to significant decreases in rilpivirine plasma concentrations^{[FDA Rilpivirine; FDA Emtricitabine/Rilpivirine/Tenofovir; FDA Emtricitabine/Rilpivirine/TAF]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Pharmacokinetics